Bris­tol-My­ers joins forces with dig­i­tal ther­a­peu­tics co; Wear­able car­diovert­er de­fib­ril­la­tor scores $145M+ in Se­ries C haul

Bris­tol-My­ers Squibb has signed on dig­i­tal ther­a­peu­tics play­er Vol­un­tis to de­vel­op a mo­bile app that will give can­cer pa­tients tips on man­ag­ing their ther­a­py and track symp­toms. Paris-based Vol­un­tis said the deal is part of its tran­si­tion to fo­cus on on­col­o­gy while drop­ping di­rect com­mer­cial­iza­tion plans for its di­a­betes busi­ness in fa­vor of a part­ner­ing strat­e­gy.

→ A US com­pa­ny de­vel­op­ing a wear­able car­diovert­er de­fib­ril­la­tor has just se­cured a mam­moth $145.6 mil­lion in Se­ries C fi­nanc­ing. The round for El­e­ment Sci­ence was led by Deer­field Health­care and Qim­ing Ven­ture Part­ners USA and in­clud­ed the par­tic­i­pa­tion of in­vestors Third Rock Ven­tures and Google Ven­tures​. Their “Jew­el patch” prod­uct ri­vals Zoll Med­ical’s LifeVest wear­able, but El­e­ment con­tends its of­fer­ing is more dis­creet and com­fort­able.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.